These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34669176)

  • 1. Efficiency and safety of eltrombopag for multi-line failed Chinese patients with immune thrombocytopenia: cases with decreased megakaryocyte response well from single-center experience.
    Liu Q; Shen Y; Li Y; Hu H; Liu W; Zhao Y; Dong H; Shen Y; Zhou Y; Ye B; Wu D
    Immunol Res; 2022 Feb; 70(1):67-74. PubMed ID: 34669176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy and safety of eltrombopag in the treatment of primary immune thrombocytopenia: real-world data from a single medical center].
    Dong XF; Li YL; Li NB; Lin WN; Wang T; Wang HQ; Li LJ; Qu W; Xing LM; Liu H; Wu YH; Wang GJ; Song J; Guan J; Wang XM; Shao ZH; Fu R
    Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):271-276. PubMed ID: 38716599
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article.
    Gao Y; Gong M; Zhang C; Kong X; Ma Y
    Medicine (Baltimore); 2017 Oct; 96(43):e8337. PubMed ID: 29069007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Multi-Center Study on the Efficacy of Eltrombopag in Management of Refractory Chronic Immune Thrombocytopenia: A Real-Life Experience.
    Çekdemir D; Güvenç S; Özdemirkıran F; Eser A; Toptaş T; Özkocaman V; Haydaroğlu Şahin H; Ermiş Turak E; Esen R; Cömert M; Sadri S; Aslaner M; Uncu Ulu B; Karakuş A; Selim Bapur D; Alacacıoğlu İ; Aydın D; Tekinalp A; Namdaroğlu S; Ceran F; Tarkun P; Kiper D; Çetiner M; Yenerel M; Demir AM; Yılmaz G; Terzi H; Atilla E; Malkan ÜY; Acar K; Öztürk E; Tombak A; Sunu C; Salim O; Alayvaz N; Sayan Ö; Ozan Ü; Ayer M; Gökgöz Z; Andıç N; Kızılkılıç E; Noyan F; Özen M; Pepedil Tanrıkulu F; Alanoğlu G; Özkan HA; Aslan V; Çetin G; Akyol Erikçi A; Deveci B; Ersoy Dursun F; Dermenci H; Aytan P; Gündüz M; Karakuş V; Özlü C; Demircioğlu S; Akay Yanar OM; Özatlı D; Ündar L; Tiftik EN; Türköz Sucak AG; Haznedaroğlu İ; Özcan M; Şencan M; Tombuloğlu M; Özet G; Bilgir O; Turgut B; Özcan MA; Payzın KB; Sönmez M; Ayyıldız O; Dal MS; Ertop Ş; Turgut M; Soysal T; Kaya E; Ünal A; Pehlivan M; Atagündüz I; Tuğlular Fıratlı T; Saydam G; Diz Küçükkaya R
    Turk J Haematol; 2019 Nov; 36(4):230-237. PubMed ID: 31327186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eltrombopag as second line treatment in patients with primary immune thrombocytopenia: A single center real life experience.
    Gardellini A; Guidotti F; Feltri M; Zancanella M; Maino E; Ambrosiani L; Turrini M
    Blood Cells Mol Dis; 2021 Dec; 92():102620. PubMed ID: 34715450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of eltrombopag in the treatment of Chinese children with chronic immune thrombocytopenia.
    Chen M; Fang JP; Zhou CX; Li XY; Lin SF; Xu LH
    Hematology; 2021 Dec; 26(1):31-36. PubMed ID: 33357172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age and Bone Marrow Cellularity are Associated with Response to Eltrombopag in Japanese Adult Immune Thrombocytopenia Patients: A Retrospective Single-Center Study.
    Uto Y; Fujiwara S; Arai N; Kawaguchi Y; Kabasawa N; Tsukamoto H; Ariizumi H; Hattori N; Saito B; Yanagisawa K; Harada H; Mori H; Shiozawa E; Nakamaki T
    Rinsho Byori; 2015 May; 63(5):548-56. PubMed ID: 26524893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eltrombopag for the treatment of refractory thrombocytopenia associated with connective tissue disease.
    Wang J; Dai M; Fu Q; Chen S
    Sci Rep; 2021 Mar; 11(1):5459. PubMed ID: 33750817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eltrombopag improves refractory thrombocytopenia in patients with Sjögren's syndrome.
    Xu L; Zhang Y; Lin N; Song X; Dai Q
    Sci Prog; 2022; 105(2):368504221102786. PubMed ID: 35603866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia.
    Garnock-Jones KP
    Drugs; 2011 Jul; 71(10):1333-53. PubMed ID: 21770480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spotlight on eltrombopag in treatment-refractory chronic primary immune thrombocytopenia.
    Garnock-Jones KP
    BioDrugs; 2011 Dec; 25(6):401-4. PubMed ID: 22050343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus.
    Maroun MC; Ososki R; Andersen JC; Dhar JP
    Lupus; 2015 Jun; 24(7):746-50. PubMed ID: 25416695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
    Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK
    Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombopoetin receptor agonist therapy in thrombocytopenia: ITP and beyond.
    Taylor A; Westwood JP; Laskou F; McGuckin S; Scully M
    Br J Haematol; 2017 May; 177(3):475-480. PubMed ID: 28295201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
    Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
    Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag.
    Tarantino MD; Fogarty PF; Shah P; Brainsky A
    Platelets; 2015; 26(1):93-6. PubMed ID: 24433306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia.
    González-López TJ; Pascual C; Álvarez-Román MT; Fernández-Fuertes F; Sánchez-González B; Caparrós I; Jarque I; Mingot-Castellano ME; Hernández-Rivas JA; Martín-Salces M; Solán L; Beneit P; Jiménez R; Bernat S; Andrade MM; Cortés M; Cortti MJ; Pérez-Crespo S; Gómez-Núñez M; Olivera PE; Pérez-Rus G; Martínez-Robles V; Alonso R; Fernández-Rodríguez A; Arratibel MC; Perera M; Fernández-Miñano C; Fuertes-Palacio MA; Vázquez-Paganini JA; Gutierrez-Jomarrón I; Valcarce I; de Cabo E; Sainz A; Fisac R; Aguilar C; Paz Martínez-Badas M; Peñarrubia MJ; Calbacho M; de Cos C; González-Silva M; Coria E; Alonso A; Casaus A; Luaña A; Galán P; Fernández-Canal C; Garcia-Frade J; González-Porras JR
    Am J Hematol; 2015 Mar; 90(3):E40-3. PubMed ID: 25400215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of eltrombopag for secondary immune thrombocytopenia in clinical practice.
    González-López TJ; Alvarez-Román MT; Pascual C; Sánchez-González B; Fernández-Fuentes F; Pérez-Rus G; Hernández-Rivas JA; Bernat S; Bastida JM; Martínez-Badas MP; Martínez-Robles V; Soto I; Olivera P; Bolaños E; Alonso R; Entrena L; Gómez-Nuñez M; Alonso A; Yera Cobo M; Caparrós I; Tenorio M; Arrieta-Cerdán E; Lopez-Ansoar E; García-Frade J; González-Porras JR
    Br J Haematol; 2017 Sep; 178(6):959-970. PubMed ID: 28573819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice.
    González-López TJ; Alvarez-Román MT; Pascual C; Sánchez-González B; Fernández-Fuentes F; Jarque I; Pérez-Rus G; Pérez-Crespo S; Bernat S; Hernández-Rivas JA; Andrade MM; Cortés M; Gómez-Nuñez M; Olivera P; Martínez-Robles V; Fernández-Rodríguez A; Fuertes-Palacio MA; Fernández-Miñano C; de Cabo E; Fisac R; Aguilar C; Bárez A; Peñarrubia MJ; García-Frade LJ; González-Porras JR
    Eur J Haematol; 2016 Sep; 97(3):297-302. PubMed ID: 26709028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
    Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
    Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.